vimarsana.com

Global Alliance For Preventing Pandemics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Clinical trial suggests convalescent plasma may improve survival with severe COVID-19

Columbia University s Mailman School of Public Health A randomized double-blind controlled trial of convalescent plasma for adults hospitalized with severe COVID-19 found that mortality at 28 days in the treatment arm was half the rate seen in the control arm (12.6% vs. 24.6%), although treatment was not associated with other improvements in clinical status. The study was led by investigators from the Center for Infection and Immunity at Columbia University Mailman School of Public Health; Columbia University Irving Medical Center; ICAP at Columbia University; Instituto Nacional de Infectologia and Hospital Federal dos Servidores do Estado in Rio de Janeiro, Brazil; University of Washington; and New York Blood Center. The results are published in the Journal of Clinical Investigation.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.